PAF-ACETHER-INDUCED DEATH IN MICE - INVOLVEMENT OF ARACHIDONATE METABOLITES AND BETA-ADRENOCEPTORS

被引:39
作者
CRISCUOLI, M
SUBISSI, A
机构
关键词
D O I
10.1111/j.1476-5381.1987.tb16841.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Intravenous Paf-acether (Paf, 15-80 .mu.g kg-1) killed conscious Swiss mice in a dose-dependent manner, without causing platelet aggregation in the lung microvasculature, or pulmonary oedema. Propranolol (0.01-10 mg/kg-1, i.p.) potentiated the effects of an LD20 of Paf dose-dependently, while the .beta.1-adrenoceptor selective antagonist, metoprolol, was three orders of magnitude less potent in this respect. Salbutamol (1 mg kg-1, i.p.) provided complete protection against an LD80 of Paf. High doses of indomethacin, aspirin, benoxaprofen and FPL 55712 given i.p. failed to inhibit the effects of an LD80 of Paf, while BW 755C (50-100 mg kg-1) exerted a dose-dependent protection and benzydamine (50 mg kg-1) and nordihydroguaiaretic acid (200 mg kg-1) were partially active. Dexamethasone (1-5 mg kg-1, s.c.) exerted a dose-dependent protein, when administered at least 4 h before Paf. In mice anesthetized with urethane, Paf (1-30 .mu.g kg-1) produced hypotension which was not clearly dose-related. The effects of the highest dose were also tested on the resistance of the lungs to inflation and found to produce bronchoconstriction. It may be concluded that pharmacological manipulation of .beta.2-adrenoceptors modulates Paf-induced death in mice, while arachidonate metabolites of the cyclo-oxygenase pathway and peptidoleukotrienes do not appear to be involved. However, lipoxygenase products, distinct from peptidoleukotrienes, may play a role in this phenomenon. It is suggested that bronchostriction, probably associated with cardiovascular effects, is a major determinant of the acute toxicity of Paf in mice.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 30 条
[21]   COMPARATIVE EFFECTS OF INDOMETHACIN, ACETYLENIC ACIDS, 15-HETE, NORDIHYDROGUAIARETIC ACID AND BW755C ON THE METABOLISM OF ARACHIDONIC-ACID IN HUMAN-LEUKOCYTES AND PLATELETS [J].
SALARI, H ;
BRAQUET, P ;
BORGEAT, P .
PROSTAGLANDINS LEUKOTRIENES AND MEDICINE, 1984, 13 (01) :53-60
[22]  
SCHELLENBERG RR, 1985, PULMONARY ANTIALLERG, P1
[23]   IS PLATELET ACTIVATING FACTOR (PAF) A MEDIATOR OF ENDOTOXIN-SHOCK [J].
TERASHITA, Z ;
IMURA, Y ;
NISHIKAWA, K ;
SUMIDA, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 109 (02) :257-261
[24]   CHARACTERIZATION OF VARIOUS ANTIALLERGIC AGENTS USING A NEW METHOD FOR INDUCING SYSTEMIC-ANAPHYLAXIS IN THE RAT [J].
UFKES, JGR ;
OTTENHOF, M .
JOURNAL OF PHARMACOLOGICAL METHODS, 1984, 11 (03) :219-226
[25]  
Vargaftig B B, 1981, Ann N Y Acad Sci, V370, P119, DOI 10.1111/j.1749-6632.1981.tb29727.x
[26]   PLATELET-ACTIVATING FACTOR INDUCES A PLATELET-DEPENDENT BRONCHOCONSTRICTION UNRELATED TO THE FORMATION OF PROSTAGLANDIN DERIVATIVES [J].
VARGAFTIG, BB ;
LEFORT, J ;
CHIGNARD, M ;
BENVENISTE, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1980, 65 (2-3) :185-192
[27]  
VARGAFTIG BB, 1986, 2ND WORLD C INFL MON
[28]  
VENUTI MC, 1985, ANNU REP MED CHEM, V20, P193
[29]  
Weiner N., 1985, PHARMACOL BASIS THER, P181
[30]   PHARMACOLOGICAL INVESTIGATION OF THE MECHANISMS OF PLATELET-ACTIVATING FACTOR INDUCED MORTALITY IN THE MOUSE [J].
YOUNG, JM ;
MALONEY, PJ ;
JUBB, SN ;
CLARK, JS .
PROSTAGLANDINS, 1985, 30 (04) :545-551